Trade Name: JEUVEAU for injection
Generic or Proper Name: (prabotulinumtoxinA-xvfs)
Sponsor: Evolus, Inc.
Approval Date: February 01, 2019
Indication: JEUVEAU is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Item</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td></td>
</tr>
<tr>
<td>Other Action Letters</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>REMS</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Multidiscipline Review(s)</td>
<td></td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Office Director</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader</td>
<td></td>
</tr>
<tr>
<td>Clinical</td>
<td></td>
</tr>
<tr>
<td>Non-Clinical</td>
<td></td>
</tr>
<tr>
<td>Statistical</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology</td>
<td></td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Reviews</td>
<td></td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td></td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:

761085Orig1s000

APPROVAL LETTER
Dear Mr. Krattenmaker:

Please refer to your Biologics License Application (BLA) dated and received May 15, 2017, and your amendments, submitted under section 351(a) of the Public Health Service Act for JEUVEAU (prabotulinumtoxinA-xvfs) for injection.

We acknowledge receipt of your resubmission dated August 2, 2018, which constituted a complete response to our May 15, 2018, action letter.

**LICENSING**

We are issuing Department of Health and Human Services U.S. License No. 2070 to Evolus, Inc., Santa Barbara, CA, under the provisions of section 351(a) of the Public Health Service Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product JEUVEAU. JEUVEAU is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

**MANUFACTURING LOCATIONS**

Under this license, you are approved to manufacture JEUVEAU at Daewoong Pharmaceutical, Co., Ltd. 35-14, Jeyakgongdan 4-Gil, Hyangnam-Eup, Hwaseong-si, Gyeonggi-Do, 18623, Republic of Korea. You may label your product with the proprietary name, JEUVEAU, and market it in 100 Units of vacuum-dried powder in a single-use vial for reconstitution.

**DATING PERIOD**

The dating period for JEUVEAU shall be 36 months from the date of manufacture when stored at 2-8 °C. The date of manufacture shall be defined as the date of final sterile filtration of the
formulated drug product. The dating period for your drug substance shall be [8] months from the date of manufacture when stored at [4]°C.

FDA LOT RELEASE

We have approved the Lot Release Protocol in your license application. Please submit results of all applicable tests. You may not distribute any lots of product until you receive a notification of release from the Director, Center for Drug Evaluation and Research (CDER).

Any changes in the manufacturing, testing, packaging, or labeling of JEUVEAU, or in the manufacturing facilities, will require the submission of information to your biologics license application for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL AND LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling and carton and container labeling submitted on January 28, 2019, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5). For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved BLA 761085.” Approval of this submission by FDA is not required before the labeling is used.
ADVISORY COMMITTEE

Your application for JEUVEAU was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because the necessary studies are impossible or highly impracticable due to low numbers of subjects in the pediatric age groups.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

3569-1 To investigate the development and implementation of a non-animal-based potency assay for drug substance and drug product release and stability testing.

The timetable you submitted on January 15, 2019, states that you will conduct this study according to the following schedule:

Final Report Submission: 01/2021

3569-2 To scale-up the reference material batch size to generate a sufficient quantity of each reference material lot to prevent frequent replacement of the reference material.

The timetable you submitted on January 15, 2019, states that you will conduct this study according to the following schedule:

Final Report Submission: 07/2021

Submit clinical protocols to your IND 121493 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing
commitments should be prominently labeled “Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the Prescribing Information, Medication Guide, and Patient Package Insert (as applicable) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266  

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80).

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
5901-B Ammendale Road  
Beltsville, MD 20705-1266
Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Compliance Risk Management and Surveillance  
10903 New Hampshire Avenue, Bldg. 51, Room 4207  
Silver Spring, MD  20903

MEDWATCH-TO-MANUFACTURER PROGRAM

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm.

POST APPROVAL FEEDBACK MEETING

New molecular entities and new biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

If you have any questions, call Strother D. Dixon, Senior Regulatory Project Manager, at (301) 796-1015.

Sincerely,

Julie Beitz, MD  
Director  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling  
- Prescribing Information  
- Medication Guide  
- Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JULIE G BEITZ
02/01/2019 01:07:21 PM